What is the official website of Pfizer Medical ?

The official website of Pfizer Medical is https://www.pfizer.com/products/information.

What is Pfizer Medical's cybersecurity risk score?

Pfizer Medical has an AI-generated cybersecurity risk score of 770 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Pfizer Medical experienced?

According to Rankiteo, Pfizer Medical currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Pfizer Medical been affected by any supply chain cyber incidents ?

According to Rankiteo, Pfizer Medical has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Pfizer Medical have SOC 2 Type 1 certification ?

According to Rankiteo, Pfizer Medical is not certified under SOC 2 Type 1.

Does Pfizer Medical have SOC 2 Type 2 certification ?

According to Rankiteo, Pfizer Medical does not hold a SOC 2 Type 2 certification.

Does Pfizer Medical comply with GDPR ?

According to Rankiteo, Pfizer Medical is not listed as GDPR compliant.

Does Pfizer Medical have PCI DSS certification ?

According to Rankiteo, Pfizer Medical does not currently maintain PCI DSS compliance.

Does Pfizer Medical comply with HIPAA ?

According to Rankiteo, Pfizer Medical is not compliant with HIPAA regulations.

Does Pfizer Medical have ISO 27001 certification ?

According to Rankiteo,Pfizer Medical is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Pfizer Medical operate in ?

Pfizer Medical operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Pfizer Medical have ?

Pfizer Medical employs approximately None employees people worldwide.

Does Pfizer Medical own any subsidiaries ?

Pfizer Medical presently has no subsidiaries across any sectors.

How many LinkedIn followers does Pfizer Medical have ?

Pfizer Medical's official LinkedIn profile has approximately followers.

What is the NAICS classification code for Pfizer Medical ?

Pfizer Medical is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Pfizer Medical have a Crunchbase profile ?

No, Pfizer Medical does not have a profile on Crunchbase.

Does Pfizer Medical have a LinkedIn profile ?

Yes, Pfizer Medical maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/pfizer-medical.

How many cybersecurity incidents has Pfizer Medical experienced ?

As of September 21, 2026, Rankiteo reports that Pfizer Medical has not experienced any cybersecurity incidents.

How many peer or competitor companies does Pfizer Medical have ?

Pfizer Medical has an estimated 5,768 peer or competitor companies worldwide.

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Pfizer Medical

Boost Score +25 with badge (5 left)

770

/1000

Fair

795

/1000

Fair

Pfizer Medical Vendor Cyber Rating & Cyber Score

pfizer.com

Add Your Compliance Badge

The goal of the Pfizer Medical LinkedIn page is to communicate emerging, trusted scientific information. The PfizerMedical LinkedIn page and associated posts are intended only for healthcare professionals. By following this Pfizer Medical LinkedIn page, you confirm that you are a healthcare professional and agree to receive information relating to the scientific data provided. Please remember that your access to any social media channel is governed by its specific Terms of Service. Pfizer fully endorses the Terms of Service of all the social media services it uses, and it is important that you abide by them. As such, we reserve the right to report posts that we believe are in breach of the general LinkedIn Agreement

Pfizer Medical

Pfizer Medical CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

No data available

Loading…

A.I.

Pfizer Medical Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Pfizer Medical

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Pfizer Medical in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Pfizer Medical in 2026.

Incident Types Pfizer Medical vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Pfizer Medical in 2026.

Incident History - Pfizer Medical (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Pfizer Medical Subsidiaries

Pfizer Medical

Pharmaceutical Manufacturing

Website: https://www.pfizer.com/products/information

Company Size: 10,001+ employees

PfizerPharmaceutical Manufacturing

Bamboo Therapeutics, Inc. a wholly owned subsidiary of Pfizer Inc.Biotechnology

Pfizer CentreOnePharmaceutical Manufacturing

Loading…

Pfizer Medical Similar Companies

Parexel

parexel.com

Parexel is a leading global clinical research organization (CRO) providing insights-driven Clinical and Consulting solutions to the world’s life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 24,000+ professionals worldwide work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind — broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare’s most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients — With Heart.™ We continue to earn recognition industrywide, including the 2025 Scrip Award for “Best Contract Research Organization – Full-Service Provider,” 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award. Community Guidelines Because Parexel’s social media channels are open to the general public and employees, we are not responsible for views expressed other than our own. However, we do not tolerate posts that are: • Abusive, harassing or threatening to others. • Defamatory, offensive, obscene, vulgar or depicting violence. • Hateful targeting by race/ethnicity, age, color, creed, religion, gender, sexual preference or orientation, nationality or political beliefs. • Sexually explicit or pornographic. • Fraudulent, deceptive, libelous, misleading or unlawful. • Referencing criminal or illegal activity. • Spamming. We reserve the right to remove comments that do not adhere to our guidelines and report users who violate the rules of our page.

Zoetis

zoetis.com

The world’s leading animal health company. We’ve been innovating ways to predict, prevent, detect, and treat animal illness for over 70 years, and we continue to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers. Our leading portfolio and pipeline makes a difference in over 100 countries. Community Guidelines: This page is intended to share how Zoetis is advancing care for animals. We aspire to create a supportive community, but there are guidelines to which posts and comments on this page must adhere. If your post references a side effect related to any Zoetis product, we may contact you for more information. To monitor the safety of Zoetis products, we advise you to call our Veterinary Medical Information and Product Support Team at 1-888-963-8471; Support Team is available Mon-Fri 9am to 6:30pm ET. We reserve the right to remove any post/comment that violates LinkedIn Guidelines. As a last resort, we reserve the right to block users that demonstrate a repeated pattern of violating LinkedIn’s spirit of constructive, professional discourse. We respectfully request that you refrain from posting comments including: Unsolicited and/or unverified medical advice Vulgarity and/or profanity Discriminatory and/or derogatory comments, hate speech Politics and religion Personal attacks and/or threats Promotion of illegal activity Copyright/trademark infringements Topics that may be considered spam/advertising Our regular business hours are Mon-Fri 9am to 5pm ET. Zoetis does not endorse and is not responsible for information and opinions shared by community members. The information shared is provided for educational purposes only and is not intended to replace discussions with an animal healthcare professional. Testimonials represent individual experience only and the experiences and opinions of community members may be unique to the speaker. Terms of Use: https://www.zoetis.com/terms-of-use

Astellas Pharma

astellas.com

Astellas is a global life sciences company committed to turning innovative science into VALUE for patients. We provide transformative therapies in disease areas that include oncology, ophthalmology, urology, immunology and women's health. Through our research and development programs, we are pioneering new healthcare solutions for diseases with high unmet medical need. Visit our Global Astellas LinkedIn Community Guidelines to learn more about interacting with this page: https://www.astellas.com/en/global-linkedin-community-guidelines

Lonza

lonza.com

Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.

Glenmark Pharmaceuticals

glenmarkpharma.com

Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the past four and a half decades, we have evolved from a generics company to a global organization offering specialty and branded products. Glenmark’s core values of Achievement, Respect, and Knowledge impart a sense of organizational unity that drives our growth. We have established a robust global branded generics, specialty, and OTC business; with a significant presence in the therapy areas of dermatology, respiratory, and oncology. Our ten state-of-the-art manufacturing facilities spread across four continents with operations in over 80 countries help us impact millions of patients across the globe. We recently consolidated our innovation efforts in small molecules and biologics research with the formation of ‘Ichnos Glenmark Innovation’ (IGI). This alliance is aimed at leveraging the capabilities of Glenmark and its subsidiary, Ichnos Sciences, to accelerate innovation in cancer treatment. To know more about IGI, check out: https://iginnovate.com/ Sustainability is an integral aspect of all our operations and we are focused on achieving our Environment, Social and Governance (ESG) goals. Our responsibility also extends to our communities, and over the years, our CSR efforts have touched the lives of over 3 million people.

Intas Pharmaceuticals

intaspharma.com

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Accord Healthcare in the EU, US, Canada, SA, Australia, APAC as well as CIS & MENA regions. Intas is present in 85+ countries, with more than 70% of its revenue coming from global business. Currently ranked 6th in the Indian pharmaceutical market, it’s the largest privately owned Indian generic pharma company. Intas has established leadership in key therapeutic segments like CNS, Cardio, Diabeto, Gastro, Urology, Oncology & Animal Health in India. We are among the top 10 generic players in the highly regulated markets of EU, US & UK. Intas operates 17 advanced formulations, R&D, and distribution facilities, of which 10 are in India and the rest in the UK, Mexico & Greece with the help of our 23,000+ Human Capital. Between them, the facilities are accredited by global regulators such as USFDA, EMA, MHRA, TGA, and others. The company invests ~6-7% of its revenues in R&D and has over 10,000 product registrations worldwide with a strategic pipeline of 300+ high-value FTF/FTM, Biosimilars, and NDDS products. Intas' highly advanced EU-GMP Certified Biopharma division is fueled by a mission to provide affordable “Biosimilars for Billions” across niche segments such as oncology, auto-immune, ophthalmology, nephrology, rheumatology, and hormone-based therapies. The Plasma Fractionation Unit of Intas Pharmaceuticals is a pioneer in manufacturing plasma-derived therapeutics. It houses a full-fledged R&D lab and a state-of-the-art WHO-GMP-certified manufacturing facility complemented with a GLP-compliant QC lab. Our values of Innovation, Customer Delight, Ownership & Collaboration, Performance Focus & Care for Society are the driving forces toward excellence.

Sandoz

sandoz.com

Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc

Merck

merck.us

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Loading…

NEWS

Pfizer Medical CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

October 07, 2025 07:00 AM

Missing Details On Trump’s Drug Price Plan Make It Hard To Evaluate

The Trump administration has reached an agreement with the drug company Pfizer to sell almost all of its medications to Medicaid at “most...

Read Article

October 03, 2025 07:00 AM

MAHA supporters not on board with Trump’s Pfizer deal

Proponents of Health and Human Services Secretary Robert F. Kennedy Jr.'s “Make America Healthy Again” (MAHA) agenda are outraged over the...

Read Article

October 02, 2025 07:00 AM

President announces TrumpRx and deal with Pfizer

The deal with Pfizer will reduce the price of the company's prescription drugs for Medicaid to Most Favored Nation pricing.

Read Article

September 03, 2025 07:00 AM

Cassidy, Pfizer CEO: Trump worthy of Nobel prize for COVID vaccine

Sen. Bill Cassidy and Pfizer CEO Albert Bourla suggest President Trump deserves a Nobel Peace Prize for rapidly distributing the COVID-19...

Read Article

August 27, 2025 07:00 AM

FDA approves COVID-19 vaccines only for ‘high risk’ people

The Food and Drug Administration (FDA) on Wednesday approved the updated version of Pfizer's and Moderna's COVID-19 vaccines for this...

Read Article

August 21, 2025 07:00 AM

Article | The fall trip to the pharmacy for a Covid shot may be strewn with obstacles

The millions of Americans who are used to getting their Covid-19 vaccines at a local pharmacy may face new hurdles this fall depending on...

Read Article

August 16, 2025 07:00 AM

TOP 50 HEALTHCARE FUTURIST SPEAKERS: MEDICAL CONSULTING EXPERTS FOR EVENTS

Top 50 healthcare futurist speakers for events: Celebrity keynote Scott Steinberg, consultant to 3000 brands. AI telemedicine pharma medical...

Read Article

August 11, 2025 07:00 AM

Cencora & The Lash Group Settle Data Breach Litigation for $40 Million

Cencora, The Lash Group, and their affiliates have agreed to pay $40 million to settle class action data breach litigation over a February...

Read Article

August 04, 2025 07:00 AM

Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave

In a notable shift, shares of Pfizer (NYSE: PFE) have recently edged higher, reflecting a burgeoning strength within the broader health...

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-94094

SUMMARY

A flaw has been found in OpenClaw up to 2026.9.5. Affected is the function createCanvasHostHandler of the file extensions/canvas/src/host/server.ts of the component Canvas Host Route. Executing a manipulation can lead to denial of service. The attack can be launched remotely. The exploit has been published and may be used. Fix suggestion's "streaming/size-limit" was never shipped - latest 2026.9.5 still buffers the whole file via readFile() (src/canvas/serve.runtime.ts:17,114), unlike the sibling WS path which caps at 64KB. The vendor was contacted early about this disclosure.

Published

Date2026-09-20

Updated

Date2026-09-20

RISK INFORMATION (Score: 4.3)

cvss2

Base Score: 4.0

Complexity: LOW

AV:N/AC:L/Au:S/C:N/I:N/A:P

cvss3

Base Score: 4.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:N/I:N/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

1.4

Exploitability

2.8

REFERENCES

CVE-2026-94093

SUMMARY

A security vulnerability has been detected in DLR-RM stable-baselines3 up to 2.9.0. This affects the function PPO.load/load_replay_buffer/VecNormalize.load of the file save_util.py. Such manipulation leads to deserialization. It is possible to launch the attack remotely. The exploit has been disclosed publicly and may be used. In v2.9.0 the PyTorch tensor load path is hardened (weights_only=True), but that hardening was later reverted on master via PR #1913 "Hotfix: revert loading with weights_only=True" [blocked] to fix PyTorch 1.13 compat - so even the one "safe" path is inconsistent across versions. #2281 was closed as a duplicate of #1831 since both are unsafe pickle deserialization - but #1831's fix (PR #41) only gated the Hugging Face Hub loader in the separate huggingface_sb3 package. This finding covers the core stable_baselines3 load APIs (PPO.load, load_replay_buffer, VecNormalize.load), which have no safe mode or gate and remained exploitable in v2.9.0 until the outstanding hardening (PR #2264) ships.

Published

Date2026-09-20

Updated

Date2026-09-20

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.1

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

CVE-2026-94092

SUMMARY

A vulnerability was detected in dmlc dgl up to 2.1.0. This impacts the function load_info/_read_torch_data of the file utils.py. Performing a manipulation of the argument path results in deserialization. The attack can be initiated remotely. The exploit is now public and may be used. The project was informed of the problem early through an issue report but has not responded yet.

Published

Date2026-09-20

Updated

Date2026-09-20

RISK INFORMATION (Score: 5.5)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.1

REFERENCES

CVE-2026-94091

SUMMARY

A weakness has been identified in piskvorky gensim up to 4.4.0. The impacted element is the function Load of the file gensim/utils.py of the component Model Loader. This manipulation of the argument fname causes deserialization. It is possible to initiate the attack remotely. The exploit has been made available to the public and could be used for attacks. Maintainer closed #3663 same-day with no comment, PR, or fix; repo's last push (2025-11-01) predates the report, so the unsafe pickle.load in SaveLoad.load remains unguarded at develop HEAD.

Published

Date2026-09-20

Updated

Date2026-09-20

RISK INFORMATION (Score: 5.5)

cvss2

Base Score: 6.5

Complexity: LOW

AV:N/AC:L/Au:S/C:P/I:P/A:P

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:U/C:L/I:L/A:L

cvss4

Base Score: 2.0

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:P/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.1

REFERENCES

CVE-2026-94090

SUMMARY

A security flaw has been discovered in JusticeRage Manalyze 1.0.0. The affected element is the function PE::_parse_debug of the file manape/pe.cpp of the component PE Parser. The manipulation of the argument misc.Length results in integer underflow. The attack may be performed from remote. The patch is identified as 3e299685759f4f767088871de58c5d07f98ee382. A patch should be applied to remediate this issue.

Published

Date2026-09-20

Updated

Date2026-09-20

RISK INFORMATION (Score: 6.3)

cvss2

Base Score: 7.5

Complexity: LOW

AV:N/AC:L/Au:N/C:P/I:P/A:P

cvss3

Base Score: 6.3

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:L/I:L/A:L

cvss4

Base Score: 5.3

Complexity: LOW

CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X

Impact Score

3.4

Exploitability

2.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…

Badge your company to reduce your risk score and your cyber insurance costs!

Trusted by insurers. Chosen by leaders.

Pfizer Medical Vendor Cyber Rating & Cyber Score

Pfizer Medical A.I CyberSecurity Scoring

Pfizer Medical CyberSecurity News & History

Pfizer Medical Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Pfizer Medical

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Pfizer Medical vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Pfizer Medical (X = Date, Y = Severity)

Pfizer Medical Subsidiaries

Pfizer Medical

Pfizer Medical Similar Companies

Parexel

Zoetis

Astellas Pharma

Lonza

Glenmark Pharmaceuticals

Intas Pharmaceuticals

Sandoz

Merck

Servier

Pfizer Medical CyberSecurity News

Missing Details On Trump’s Drug Price Plan Make It Hard To Evaluate

MAHA supporters not on board with Trump’s Pfizer deal

President announces TrumpRx and deal with Pfizer

Cassidy, Pfizer CEO: Trump worthy of Nobel prize for COVID vaccine

FDA approves COVID-19 vaccines only for ‘high risk’ people

Article | The fall trip to the pharmacy for a Covid shot may be strewn with obstacles

TOP 50 HEALTHCARE FUTURIST SPEAKERS: MEDICAL CONSULTING EXPERTS FOR EVENTS

Cencora & The Lash Group Settle Data Breach Litigation for $40 Million

Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo

Pfizer Medical CyberSecurity News & History

Pfizer Medical Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Incident Predictions locked

A.I Risk Score Likelihood 3 - 6 - 9 months

A.I. Risk Score Predictions locked

Underwriter Stats for Pfizer Medical

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incidents vs All-Companies Average (This Year)

Incident Types Pfizer Medical vs Pharmaceutical Manufacturing Industry Avg (This Year)

Incident History - Pfizer Medical (X = Date, Y = Severity)

Pfizer Medical Subsidiaries

Pfizer Medical

Pfizer Medical Similar Companies

Parexel

Zoetis

Astellas Pharma

Lonza

Glenmark Pharmaceuticals

Intas Pharmaceuticals

Sandoz

Merck

Servier

Pfizer Medical CyberSecurity News

Missing Details On Trump’s Drug Price Plan Make It Hard To Evaluate

MAHA supporters not on board with Trump’s Pfizer deal

President announces TrumpRx and deal with Pfizer

Cassidy, Pfizer CEO: Trump worthy of Nobel prize for COVID vaccine

FDA approves COVID-19 vaccines only for ‘high risk’ people

Article | The fall trip to the pharmacy for a Covid shot may be strewn with obstacles

TOP 50 HEALTHCARE FUTURIST SPEAKERS: MEDICAL CONSULTING EXPERTS FOR EVENTS

Cencora & The Lash Group Settle Data Breach Litigation for $40 Million

Pfizer's Ascent Signals Broader Health Sector Resilience Amidst Innovation Wave

Global CVEs (Not Company-Specific)

Access Data Using Our API

What Do We Measure ?

These are some of the factors we use to calculate the overall score:

Rankiteo